Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Systematic Review Article

阿尔茨海默病精神病的新希望：匹莫范色林

卷 20, 期 6, 2023

发表于: 11 September, 2023

页: [403 - 408] 页: 6

弟呕挨: 10.2174/1567205020666230825124922

价格: $65

conference banner
摘要

阿尔茨海默病（AD）在全球痴呆症病因中排名第一。AD可以以显著的速度发展为精神病症状。增设精神病门诊可使AD预后恶化。美国食品药品监督管理局（FDA）没有批准抗精神病药物治疗阿尔茨海默病精神病（ADP）。然而，匹马万丝氨酸，一种非典型抗精神病药物，已被美国食品药品监督管理局批准用于治疗帕金森病。据预测，新的抗精神病药物匹马万塞林将填补这一领域的重要空白。在临床试验中，它似乎对治疗帕金森氏症和AD患者的精神病妄想和幻觉有效。在这篇系统综述中，我们评估了对ADP中使用的匹马万色林的现有文献数据的分析。我们检索了关于匹马万塞林治疗ADP的临床研究的现有文献。数据是通过系统搜索PubMed、MEDLINE、EMBASE和Google Scholar确定的，直到2022年12月。总共有35个引文被发现并上传到Mendeley程序中。对文献资料的摘要和全文进行了检查。观察了匹马万色林对ADP的治疗效果。匹马万色林具有独特的作用机制。Pimavanserin是一种非典型抗精神病药物，对5-HT2C受体的亲和力较低，并具有选择性5-HT2A反向激动剂/拮抗剂作用。Pimavanserin对多巴胺能、组胺能、毒蕈碱能或肾上腺素能受体没有临床意义的亲和力。这种药剂也可以在抗药性精神病治疗中取得显著的积极结果。

关键词: 阿尔茨海默病、精神病、抗精神病药、匹莫范色林、痴呆症、帕金森病。

« Previous Next »
[1]
Dementia: Number of people affected to triple in next 30 years. Available from:https://www.who.int/news/item/07-12-2017-dementia-number-of-people-affected-to-triple-in-next-30-years (Accessed on: 15 December 2022).
[2]
Haupt, M.; Kurz, A.; Jänner, M. A 2-year follow-up of behavioral and psychological symptoms in Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2000, 11(3), 147-152.
[3]
Ropacki, S.A.; Jeste, D.V. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: A review of 55 studies published from 1990 to 2003. Am. J. Psychiatry, 2005, 162(11), 2022-2030.
[http://dx.doi.org/10.1176/appi.ajp.162.11.2022] [PMID: 16263838]
[4]
Zuidema, S.U.; Johansson, A.; Selbaek, G.; Murray, M.; Burns, A.; Ballard, C. A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practice. Int. Psychogeriatr., 2015, 27(11), 1849-59.
[http://dx.doi.org/10.1017/S1041610215000745] [PMID: 26062126]
[5]
Paulsen, J.; Salmon, D.; Thal, L.; Neurology, R.R. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology, 2000, 54(10), 1965-71.
[http://dx.doi.org/10.1212/WNL.54.10.1965]
[6]
Bessey, L.J.; Walaszek, A. Management of behavioral and psychological symptoms of dementia. Curr. Psychiatry Rep., 2019, 21(8), 66.
[http://dx.doi.org/10.1007/s11920-019-1049-5] [PMID: 31264056]
[7]
Caraci, F.; Santagati, M.; Caruso, G.D.C. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: Focus on brexpiprazole and pimavanserin. F1000Res., 2020, 9, F1000-686.
[http://dx.doi.org/10.12688/f1000research.22662.1]
[8]
Stern, Y.; Albert, M.; Brandt, J.; Jacobs, D.; Neurology, M.T. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: Prospective analyses from the Predictors Study. Neurology, 1994, 44(12), 2300-7.
[http://dx.doi.org/10.1212/WNL.44.12.2300]
[9]
Peters, M.; Schwartz, S. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: The cache county study. Am. Assoc. Geria. Psych., 2014, 22(3)
[10]
Wang, X.; Zhou, Y.; He, S.; Ouyang, Z.; Feng, L.; Shen, Y.; Wu, X.; Sun, Y.; Wu, X.; Xu, Q. Obaculactone exerts a novel ameliorating effect on contact dermatitis through regulating T lymphocyte. Int. Immunopharmacol., 2015, 28(1), 1-9.
[http://dx.doi.org/10.1016/j.intimp.2015.05.015] [PMID: 26003846]
[11]
Murray, P.; Kumar, S. Psychosis in Alzheimer's disease. Biol. Psychiatry, 2014, 75(7), 542-552.
[12]
Ballard, C.; Banister, C.; Khan, Z.; Cummings, J.; Demos, G.; Coate, B. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: A phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol., 2018, 17(3), 213-222.
[13]
Schneider, L.S.; Frangakis, C.; Drye, L.T.; Devanand, D.P.; Marano, C.M.; Mintzer, J.; Mulsant, B.H.; Munro, C.A.; Newell, J.A.; Pawluczyk, S.; Pelton, G.; Pollock, B.G.; Porsteinsson, A.P.; Rabins, P.V.; Rein, L.; Rosenberg, P.B.; Shade, D.; Weintraub, D.; Yesavage, J.; Lyketsos, C.G. Heterogeneity of treatment response to citalopram for patients with Alzheimer’s disease with aggression or agitation: The citad randomized clinical trial. Am. J. Psychiatry, 2016, 173(5), 465-472.
[http://dx.doi.org/10.1176/appi.ajp.2015.15050648] [PMID: 26771737]
[14]
Coate, B.; Ballard, C.G.; Abler, V. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis. Am. Assoc. Geria. Psych., 2020, 35(11), 1402-1408.
[15]
Cummings, J. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am. Assoc. Geria. Psych., 1998, 6(2), S64-S78.
[16]
McIlroy, S.; David, C. Neurobiology and genetics of behavioral syndromes of Alzheimer's disease. Curr. Alzheimer Res., 2004, 1(2), 135-42.
[17]
Zubenko, G.; Moossy, J.; Martinez, A. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch. Neurol., 1991, 48(6), 619-624.
[18]
Tekin, S.; Mega, M.S.; Masterman, D.M.; Chow, T.; Garakian, J.; Vinters, H.V.; Cummings, J.L. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann. Neurol., 2001, 49(3), 355-361.
[http://dx.doi.org/10.1002/ana.72] [PMID: 11261510]
[19]
Victoroff, J.; Zarow, C.; Mack, W. Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer's disease. Arch. Neurol., 1996, 53(2), 428-434.
[20]
Sweet, R.; Pollock, B. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer's disease. Int. Psychogeriatr., 2001, 13(4), 401-409.
[21]
Kales, H.; Lyketsos, C. Management of behavioral and psychological symptoms in people with Alzheimer's disease: An international Delphi consensus. Int. Psychogeriatr., 2018, 31(1), 83-90.
[22]
Ballard, C.; Gauthier, S. Management of agitation and aggression associated with Alzheimer's disease. Nat. Rev. Neurol., 2009, 5, 245-255.
[23]
Tampi, R. Antipsychotic use in dementia: A systematic review of benefits and risks from meta-analyses. Ther. Adv. Chronic Dis., 2016, 7(5), 229-245.
[24]
Mittal, V.; Kurup, L.; Williamson, D.; Muralee, S.; Tampi, R.R. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: A literature review of evidence. Am. J. Alzheimer's Dis. Other Dement., 2011, 26(1), 10-28.
[http://dx.doi.org/10.1177/1533317510390351]
[25]
Home - Acadia Pharmaceuticals. Available from:https://acadia.com/ (Accessed on: 20 December 2022).
[26]
Srinivasan, S.; Tampi, R. Pimavanserin for the treatment of psychosis in Alzheimer's disease: A literature review. World J. Psychiatry, 2020, 10(7), 162-174.
[27]
Ballard, C.; Youakim, J.M.; Coate, B.; Stankovic, S. Pimavanserin in alzheimer’s disease psychosis: Efficacy in patients with more pronounced psychotic symptoms. J. Prev. Alzheimers Dis., 2019, 6(1), 27-33.
[PMID: 30569083]
[28]
Tariot, PN; Cummings, JL; Soto-Martin, ME; Ballard, C; Erten-Lyons, D; Sultzer, DL Trial of pimavanserin in dementia-related psychosis. N. Engl. J. Med., 2021, 385(4), 309-19.
[29]
Horn, S.; Richardson, H.; Xie, S. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. Parkinsonism Relat. Disord., 2019, 69, 119-124.
[30]
Nasrallah, H.; Fedora, R. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Schizophr Res., 2019, 208, 217-220.
[31]
Crump, C.J.; Litteral, C.A.; Elsayed, O.H.; El-Mallakh, R.S. Pimavanserin for bipolar disorder. Bipolar Disord., 2022, 24(6), 697-699.
[http://dx.doi.org/10.1111/bdi.13191] [PMID: 35167172]
[32]
Bugarski-Kirola, D.; Arango, C.; Fava, M.; Nasrallah, H.; Liu, I.Y.; Abbs, B.; Stankovic, S. Pimavanserin for negative symptoms of schizophrenia: Results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry, 2022, 9(1), 46-58.
[http://dx.doi.org/10.1016/S2215-0366(21)00386-2] [PMID: 34861170]
[33]
Yasue, I.; Matsunaga, S. Serotonin 2A receptor inverse agonist as a treatment for parkinson's disease psychosis: A systematic review and meta-analysis of serotonin 2a receptor negative modulators. J. Alzheimers Dis., 2016, 50(3), 733-40.
[34]
Fava, M.; Dirks, B.; Freeman, M.P.; Papakostas, G.I.; Shelton, R.C.; Thase, M.E.; Trivedi, M.H.; Liu, K.; Stankovic, S. A phase 2, randomized, double-blind, placebo-controlled ST of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY). J. Clin. Psychiatry, 2019, 80(6)
[http://dx.doi.org/10.4088/JCP.19m12928]
[35]
Ancoli-Israel, S.; Vanover, K.E.; Weiner, D.M.; Davis, R.E.; van Kammen, D.P. Pimavanserin tartrate, a 5-HT2A receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med., 2011, 12(2), 134-141.
[http://dx.doi.org/10.1016/j.sleep.2010.10.004] [PMID: 21256805]

Rights & Permissions Print Cite
Article Metrics
47
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy